Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) issued its earnings results on Thursday. The company reported ($7.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($5.53), FiscalAI reports. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.02 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.

Lyell Immunopharma Stock Down 1.5%

LYEL traded down $0.37 on Thursday, reaching $24.77. 95,845 shares of the company traded hands, compared to its average volume of 105,309. The company has a market cap of $526.11 million, a P/E ratio of -1.08 and a beta of -0.14. Lyell Immunopharma has a one year low of $7.65 and a one year high of $45.00. The firm has a fifty day simple moving average of $24.41 and a two-hundred day simple moving average of $21.37.

Analyst Upgrades and Downgrades

Several research firms have commented on LYEL. Citizens Jmp began coverage on shares of Lyell Immunopharma in a research report on Monday. They set a “market outperform” rating and a $34.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. Finally, HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price target for the stock from $20.00 to $45.00 in a research note on Tuesday, December 9th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $39.50.

Insiders Place Their Bets

In other news, insider Gary K. Lee sold 1,671 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $39,084.69. Following the transaction, the insider directly owned 16,938 shares of the company’s stock, valued at approximately $396,179.82. This trade represents a 8.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Stephen J. Hill sold 1,236 shares of Lyell Immunopharma stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $28,910.04. Following the sale, the chief operating officer directly owned 17,795 shares of the company’s stock, valued at $416,225.05. This represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 11,310 shares of company stock worth $264,285 in the last three months. Corporate insiders own 22.30% of the company’s stock.

Institutional Trading of Lyell Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. GSK plc purchased a new position in Lyell Immunopharma in the fourth quarter valued at about $46,560,000. ARCH Venture Management LLC boosted its holdings in shares of Lyell Immunopharma by 51.5% in the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after acquiring an additional 938,438 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after acquiring an additional 336,378 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.